Sartorius AG Reports Mixed Half-Year Performance Amid Volatile Market

Göttingen, July 18, 2024 — Sartorius AG has disclosed its half-year results, noting moderate revenue growth in Q2 but overall muted demand recovery. The company has revised its full-year outlook to a more cautious stance, citing persistent market volatility.

Sales revenue decreased by 2.2% in the first six months but grew by 3.6% in Q2. The underlying EBITDA margin remained robust at 28.1%. The Bioprocess Solutions Division matched last year's revenue, while the Lab Products & Services Division faced challenges due to the Chinese market.

CEO Joachim Kreuzburg stated that Sartorius met its initial targets but observed a reluctance from customers to place new orders. The company now projects full-year revenue to align closely with the prior year, expecting demand to pick up only in the final quarter.

Long-term trends remain positive, driven by the healthcare and biotechnology sectors, particularly cell and gene therapies. Despite short-term uncertainties, Sartorius maintains its mid-term growth targets up to 2028.